Tiers lieu: UXCARE
Led by: GIP Genopole
Key consortium members: Centre Hospitalier Sud-Francilien (CHSF), Société d’Accélération de Transfert Technologique (SATT) Paris-Saclay, European Institute of Innovation and Technology (EIT) Health France, Centre d'Étude et de Recherche sur l'Intensification du Traitement du Diabète (CERITD)
The UXCARE Tiers-lieu focuses on innovative digital solutions designed to improve diabetes care. It facilitates the design of new products, services, and care pathways centered on user needs, and enables companies and healthcare facilities with technologically advanced solutions to test them in real-world settings and roll them out under optimal conditions.
The Tiers-Lieu's Services
UXCARE provides healthcare companies and professionals with an optimal testing environment for evaluating and rolling out new healthcare technologies on a regional scale.
UXCARE is based on an innovative healthcare model combining:
- A leading university hospital department in diabetology, recognized for its expertise and numerous pilot initiatives in digital health and community care;
- 3 “non-hospital” care facilities and a mobile medical team providing a bridge between the community and the hospital to reach vulnerable and at-risk populations (adolescents, young adults, the elderly, etc.);
- A specialized “diabetic foot” unit providing multidisciplinary follow-up and optimized patient care (a cohort of over 300 patients);
- A multidisciplinary team (dietitian, psychologist, etc.) and medical-social services.
The UXCARE Tiers-Lieu offers a comprehensive support pathway from design through to market launch:
- 360° audit and strategic mentoring;
- Management and oversight of real-world field trials (access to infrastructure and monitoring data to test the effectiveness and acceptability of digital solutions, medico-economic studies);
- Regulatory and certification consulting;
- Market access strategy and procurement policy;
- Open innovation program.
The Tiers-Lieu Projects
Project: MFDeep
Solution Provider: NeuTigers France
Solution: MFDeep is an innovative digital solution based on artificial intelligence, designed to improve the prediction of fetal macrosomia in pregnant women with or at risk of developing gestational diabetes. Through the continuous collection and analysis of physiological signals from wearable sensors integrated into a smartwatch, MFDeep aims to offer an accessible, non-invasive, real-time approach to facilitate earlier risk detection and more proactive, personalized obstetric care.
Need: Gestational diabetes is associated with an increased risk of fetal macrosomia, which can lead to major obstetric complications such as shoulder dystocia, preterm births, instrumental deliveries, and certain avoidable cesarean sections. Currently, fetal weight estimation relies primarily on ultrasound, whose predictive performance remains limited. MFDeep aims to improve the prediction of fetal macrosomia through continuous multimodal physiological monitoring combined with artificial intelligence.
Contribution of the Tiers-Lieu: The UXCARE Tiers-Lieu is supporting NeuTigers in the implementation of a RIPH2 (Category 2 Research Involving Human Subjects) observational study conducted at the Centre Hospitalier Sud Francilien (CHSF). This study constitutes the foundational step of the MFDeep project by establishing the framework for collecting the physiological, clinical, biological, and obstetric data necessary for the future development and training of the MFDeep algorithm. It also lays the methodological and regulatory groundwork essential for the solution’s future clinical validation phases.
Project: PREDIDIAB
Solution provider: PrediDIAB
Solution: PrediDIAB is a predictive test designed for young adults with a parent who has diabetes. It combines a clinical questionnaire with genetic analysis based on a saliva test to estimate the probability and age of onset of type 2 diabetes, thereby enabling personalized prevention.
Need: Type 2 diabetes is a chronic disease with a rapidly rising incidence, often diagnosed late. Currently, existing predictive tools offer limited discrimination and come too late in patients’ lives. PrediDIAB aims to identify at-risk individuals early so that tailored prevention strategies can be offered.
Contribution of the Tiers-Lieu: The UXCARE Tiers-lieu facilitates clinical trials of the PrediDIAB test, particularly through the CHSF and its diabetes care network. The prospective clinical study aims to validate the test’s efficacy compared to existing predictive tools and to collect the data necessary for its CE marking, with a view to integrating it into the diabetes prevention pathway.